Similar articles

• [Preoperative application of NK 631 for carcinoma of oral cavity (author's transl)].

  Yamamoto E, Sunakawa H, Kohama GI. Yamamoto E, et al. Jpn J Antibiot. 1979 Feb;32(2):253-8. Jpn J Antibiot. 1979. PMID: 86621 Japanese. No abstract available.
• [Clinical experience with pepleomycin (NK 631) (author's transl)].

  Hashimoto K, Shioda S, Amagasa T, Shimizu M, Sato O, Ito H, Fujibayashi T, Soda T. Hashimoto K, et al. Jpn J Antibiot. 1979 Mar;32(3):451-62. Jpn J Antibiot. 1979. PMID: 86627 Japanese. No abstract available.
• [Studies on the clinical effect of NK 631 for oral-cavity cancers (author's transl)].

  Ohashi Y, Abe M, Saito K, Mizutani H, Onishi S, Ueda N. Ohashi Y, et al. Jpn J Antibiot. 1979 Feb;32(2):259-64. Jpn J Antibiot. 1979. PMID: 86622 Japanese. No abstract available.
• [Primary effect of NK 631 against head-and-neck cancers (author's transl)].

  Takata K, Honda T. Takata K, et al. Jpn J Antibiot. 1979 Jan;32(1):106-14. Jpn J Antibiot. 1979. PMID: 84880 Japanese. No abstract available.
• [Clinical effects of NK 631, a new bleomycin derivative, in treatment of oral cancer (author's transl)].

  Kajiyama M, Dohjyo M, Ohno A, Nagasaka K, Yamaguma M, Okabe T, Terasaka S. Kajiyama M, et al. Jpn J Antibiot. 1979 Jan;32(1):129-37. Jpn J Antibiot. 1979. PMID: 84883 Japanese.